Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 13

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 13
---
 diseases. We will use any remaining net proceeds for general corporate purposes and working capital. See "Use of Proceeds."                                                             |
| Voting rights        | Each outstanding common share will be entitled to one vote on all matters submitted to a vote of shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Listings             | Our common shares and Public Warrants are listed on the Nasdaq under the symbols "MDCX" and "MDCXW," respectively. The warrants offered hereby will not be listed on any U.S. securities exchange.                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dividend policy      | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. |
| Risk factors         | See "Risk Factors" and the other information included in this offering circular for a discussion of factors you should consider before deciding to invest in our common shares and warrants.                                                                                                                                                                                                                                                                                                                                                                                                        |

<div align='center'>- 5 -</div>

Except as otherwise noted, all information contained in this offering circular assumes:

•no purchase of common shares or warrants in this offering by directors, officers or existing shareholders; and

•no exercise of our outstanding options (as described herein) and Public Warrants, or the warrants offered in this offering.

The number of common shares that will be outstanding after this offering is based on 11,922,561 common shares outstanding as of March 6, 2025.

Continuing Reporting Requirements Under Regulation A

We are required to file periodic and other reports with the SEC, pursuant to the requirements of Section 13(a) of the Exchange Act. Our continuing reporting obligations under Regulation A are deemed to be satisfied as long as we comply with our Section 13(a) reporting requirements.

<div align='center'>- 6 -

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this offering circular.

We have derived